| Name | Company | P/L % | MPV |
|
|---|---|---|---|---|
| Lord Glendonbrook |
|
Stryker / NYQ:SYK | 389.43% | £342,598.69 |
| Lord Glendonbrook |
|
Abbott Laboratories / NYQ:ABT | 324.24% | £296,969.07 |
| Lord Sassoon |
|
Abbott Laboratories / NYQ:ABT | 225.81% | £228,063.82 |
| Lord Grabiner |
|
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
| Baroness Noakes |
|
Smith & Nephew / NYQ:SNN | 54.14% | £107,900.75 |
| Lord Glendonbrook |
|
Smith & Nephew / NYQ:SNN | 43.07% | £100,145.80 |
| Lord Mance |
|
Stryker / NYQ:SYK | 23.55% | £86,484.37 |
| Lord Glendonbrook |
|
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
| Lord Londesborough |
|
Abbott Laboratories / NYQ:ABT | -1.50% | £68,951.48 |
| Lord Howard of Rising |
|
Ekf Diagnostics / LSE:EKF.L | -2.84% | £68,012.25 |
| Lord Sassoon |
|
Medtronic / NYQ:MDT | -13.79% | £60,344.35 |
| Lord Glendonbrook |
|
Align Technology / NMS:ALGN | -35.62% | £45,068.49 |
| Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** | |
| Lord Browne of Madingley | Allurion / NYQ:ALUR | -75.83% | £16,918.43 |